1. Home
  2. CDNA vs ARQT Comparison

CDNA vs ARQT Comparison

Compare CDNA & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CDNA
  • ARQT
  • Stock Information
  • Founded
  • CDNA 1998
  • ARQT 2016
  • Country
  • CDNA United States
  • ARQT United States
  • Employees
  • CDNA N/A
  • ARQT N/A
  • Industry
  • CDNA Medical Specialities
  • ARQT Biotechnology: Pharmaceutical Preparations
  • Sector
  • CDNA Health Care
  • ARQT Health Care
  • Exchange
  • CDNA Nasdaq
  • ARQT Nasdaq
  • Market Cap
  • CDNA 1.1B
  • ARQT 1.1B
  • IPO Year
  • CDNA 2014
  • ARQT 2020
  • Fundamental
  • Price
  • CDNA $22.34
  • ARQT $13.85
  • Analyst Decision
  • CDNA Buy
  • ARQT Strong Buy
  • Analyst Count
  • CDNA 8
  • ARQT 5
  • Target Price
  • CDNA $26.43
  • ARQT $17.00
  • AVG Volume (30 Days)
  • CDNA 768.6K
  • ARQT 1.8M
  • Earning Date
  • CDNA 02-26-2025
  • ARQT 02-25-2025
  • Dividend Yield
  • CDNA N/A
  • ARQT N/A
  • EPS Growth
  • CDNA N/A
  • ARQT N/A
  • EPS
  • CDNA N/A
  • ARQT N/A
  • Revenue
  • CDNA $312,775,000.00
  • ARQT $138,708,000.00
  • Revenue This Year
  • CDNA $19.85
  • ARQT $215.24
  • Revenue Next Year
  • CDNA $11.34
  • ARQT $53.63
  • P/E Ratio
  • CDNA N/A
  • ARQT N/A
  • Revenue Growth
  • CDNA 5.26
  • ARQT 182.84
  • 52 Week Low
  • CDNA $7.42
  • ARQT $4.83
  • 52 Week High
  • CDNA $34.84
  • ARQT $16.20
  • Technical
  • Relative Strength Index (RSI)
  • CDNA 48.07
  • ARQT 51.96
  • Support Level
  • CDNA $22.06
  • ARQT $12.61
  • Resistance Level
  • CDNA $23.56
  • ARQT $14.29
  • Average True Range (ATR)
  • CDNA 1.79
  • ARQT 0.96
  • MACD
  • CDNA 0.07
  • ARQT -0.18
  • Stochastic Oscillator
  • CDNA 25.72
  • ARQT 34.54

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Share on Social Networks: